A Phase 1/2 trial to study the effect of SY-1365 for the treatment of patient with acute leukemia

Trial Profile

A Phase 1/2 trial to study the effect of SY-1365 for the treatment of patient with acute leukemia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs SY 1365 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Syros Pharmaceuticals
  • Most Recent Events

    • 15 May 2017 Syros plans to initiate this trial based on the data from other trial (see profile 279117), as reported in a company media release.
    • 26 Apr 2016 New trial record
    • 20 Apr 2016 According to a Syros Pharmaceuticals media release, company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the second half of 2016 with the goal of initiating this study in acute leukemia in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top